{
  "ticker": "PIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960285",
  "id": "02960285",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250620",
  "time": "0836",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250620/pdf/06kxwnhnd4h5k9.pdf",
  "summary": "### Summary of Material Information:  \n\n- **Product Launch:** Proteomics International (ASX: PIQ) launches **PromarkerD**, a predictive blood test for diabetic kidney disease (DKD), in the **US market** via its **CLIA-certified lab in California**.  \n- **Market Opportunity:**  \n  - Targets **32M+ US diabetics**, addressing a **$130B+ annual healthcare cost** linked to DKD.  \n  - Initial rollout in **California**, with plans for broader US expansion.  \n- **Commercial Strategy:** Hybrid approach combining **direct-to-consumer (DTC) sales** and **partnership/licensing discussions** with insurers/distributors.  \n- **Clinical Validation:** Test predicts DKD **up to 4 years in advance** with **86% accuracy** in studies.  \n- **Catalyst:** Launch coincides with **ADA Scientific Sessions** (key industry event) and includes a **Late-Breaking Abstract presentation**.  \n\n*No capital raising, financials, or trading halt details identified.*",
  "usage": {
    "prompt_tokens": 2199,
    "completion_tokens": 215,
    "total_tokens": 2414,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-19T22:47:02.265155"
}